Clinical burden of relapses in aquaporin-4 immunoglobulin G-positive neuromyelitis optica spectrum disorder: A single center cohort analysis.
Neuromyelitis spectrum disorder
Neuropathic pain
Optic neuritis
Transverse myelitis
Journal
Journal of neuroimmunology
ISSN: 1872-8421
Titre abrégé: J Neuroimmunol
Pays: Netherlands
ID NLM: 8109498
Informations de publication
Date de publication:
15 01 2022
15 01 2022
Historique:
received:
23
07
2021
revised:
25
10
2021
accepted:
31
10
2021
pubmed:
26
11
2021
medline:
25
2
2022
entrez:
25
11
2021
Statut:
ppublish
Résumé
A retrospective, observational analysis of 47 patients with aquaporin-4 immunoglobulin G-positive neuromyelitis optica spectrum disorder (AQP4-IgG+ NMOSD) enrolled at the University of Utah healthcare system was conducted. Visual acuity, neurological disability, and pain medication use were compared in relapsing versus non-relapsing patients. The median observation period was 3.6 years (range: 0.0-11.4 years); the annual relapse rate was 0.1376 (95% confidence interval: 0.0874, 0.191). Relapsing patients (n = 14) exhibited diminished visual acuity, clinically meaningful worsening of neurological disability, and greater pain medication use than non-relapsing patients (n = 33). Therapies that reduce the risk of relapses should be considered when making treatment decisions.
Identifiants
pubmed: 34823121
pii: S0165-5728(21)00288-5
doi: 10.1016/j.jneuroim.2021.577761
pii:
doi:
Substances chimiques
AQP4 protein, human
0
Aquaporin 4
0
Autoantibodies
0
Autoantigens
0
Immunoglobulin G
0
Types de publication
Journal Article
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
577761Informations de copyright
Copyright © 2021 The Authors. Published by Elsevier B.V. All rights reserved.